Magnitude and correlates of virological failure among adult HIV patients receiving PI based second line ART regimens in north western Tanzania; a case control study

[1]  Brian C. Zanoni,et al.  Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure , 2017, Journal of the International AIDS Society.

[2]  A. De Luca,et al.  Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique , 2017, BMC Infectious Diseases.

[3]  M. Fox,et al.  Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa , 2017, AIDS patient care and STDs.

[4]  A. Harries,et al.  Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar , 2017, Global health action.

[5]  M. Wubshet,et al.  Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study , 2016, BMJ Open.

[6]  G. Shakya,et al.  Virological and Immunological Status of the People Living with HIV/AIDS Undergoing ART Treatment in Nepal , 2016, BioMed research international.

[7]  W. Fawzi,et al.  HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. , 2016, The Journal of antimicrobial chemotherapy.

[8]  S. Kibusi,et al.  Late-stage disease at presentation to an HIV clinic in eastern Tanzania: A retrospective cross-sectional study. , 2015, Malawi medical journal : the journal of Medical Association of Malawi.

[9]  S. Sundar,et al.  Outcome of patients on second line antiretroviral therapy under programmatic condition in India , 2015, BMC Infectious Diseases.

[10]  J. Farrar,et al.  Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam , 2015, Medicine.

[11]  Zewdneh Shewamene,et al.  Determinants of non-adherence to antiretroviral therapy in adult hospitalized patients, Northwest Ethiopia , 2015, Patient preference and adherence.

[12]  J. Bartlett,et al.  Association of First-Line and Second-Line Antiretroviral Therapy Adherence , 2014, Open forum infectious diseases.

[13]  R. Baltussen,et al.  Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study , 2014, Journal of the International AIDS Society.

[14]  R. Dikshit,et al.  Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients , 2013, Perspectives in clinical research.

[15]  B. Kidenya,et al.  Plasma Concentrations of Efavirenz and Nevirapine among HIV-Infected Patients with Immunological Failure Attending a Tertiary Hospital in North-Western Tanzania , 2013, PloS one.

[16]  T. F. Rinke de Wit,et al.  Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. , 2012, The Journal of infectious diseases.

[17]  N. Ford,et al.  Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis , 2012, AIDS.

[18]  K. Freedberg,et al.  Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa , 2012, PloS one.

[19]  W. Stevens,et al.  Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. , 2012, AIDS research and human retroviruses.

[20]  M. Maathuis,et al.  The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring , 2012, AIDS.

[21]  G. V. Van Zyl,et al.  HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-Naïve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High , 2011, PloS one.

[22]  A. Rodger,et al.  Association of Age with Mortality and Virological and Immunological Response to Antiretroviral Therapy in Rural South African Adults , 2011, PloS one.

[23]  J. Nachega,et al.  Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting , 2011, Journal of acquired immune deficiency syndromes.

[24]  D. Katzenstein,et al.  Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa , 2011, PloS one.

[25]  L. Ferradini,et al.  Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV‐infected patients in Cambodia , 2011, Tropical medicine & international health : TM & IH.

[26]  L. Ferradini,et al.  High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia , 2011, Journal of the International AIDS Society.

[27]  A. Calmy,et al.  Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. , 2010, JAMA.

[28]  D. Katzenstein,et al.  Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa , 2010, AIDS (London).

[29]  M. Fox,et al.  High Rates of Survival, Immune Reconstitution, and Virologic Suppression on Second-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.

[30]  J. Hogan,et al.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  O. Onwujekwe,et al.  Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. , 2009, Health policy and planning.

[32]  Mark J van der Laan,et al.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification , 2008, AIDS.

[33]  M. Kolber.  CD38+CD8+ T-cells negatively correlate with CD4 central memory cells in virally suppressed HIV-1-infected individuals. , 2008, AIDS (London).

[34]  S. Hugonnet,et al.  Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. , 2006, The Journal of infectious diseases.